From microvasculature to fibroblasts: Contribution of anti-endothelial cell antibodies in systemic sclerosis

International Journal of Immunopathology and Pharmacology

Volumn 28, Issue 1, 2015, Pages 93-103

  Corallo, C ^a   Franci, B ^a   Lucani, B ^a   Montella, A ^a   Chirico, C ^a   Gonnelli, S ^a   Nuti, R ^a   Giordano, N ^a  

^a UNIVERSITY OF SIENA   (Italy)

Author keywords

AECA; Fibroblasts; Microvascular endothelial cells; Systemic sclerosis

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; COLLAGEN TYPE 1; ENDOTHELIAL CELL ANTIBODY; ENDOTHELIN 1; TRANSFORMING GROWTH FACTOR BETA; ACTA2 PROTEIN, HUMAN; ACTIN; ANTI-ENDOTHELIAL CELL ANTIBODY; AUTOANTIBODY; CONDITIONED MEDIUM;

ADULT; AGED; APOPTOSIS; ARTICLE; CAPILLARY ENDOTHELIAL CELL; CELL ACTIVATION; CELL PROLIFERATION; CELL STIMULATION; CLINICAL ARTICLE; COLLAGEN SYNTHESIS; CONTROLLED STUDY; CULTURE MEDIUM; DISEASE DURATION; FEMALE; FIBROBLAST; FIBROBLAST CULTURE; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; IMMUNOASSAY; PRIORITY JOURNAL; SCLERODERMA; SKIN FIBROBLAST; SYSTEMIC SCLEROSIS; UPREGULATION; CELL CULTURE; CONDITIONED MEDIUM; ENDOTHELIUM; ENDOTHELIUM CELL; IMMUNOLOGY; METABOLISM; MICROVASCULATURE; MIDDLE AGED; PATHOLOGY; SKIN;

ACTINS; AUTOANTIBODIES; CELLS, CULTURED; COLLAGEN TYPE I; CULTURE MEDIA, CONDITIONED; ENDOTHELIAL CELLS; ENDOTHELIN-1; ENDOTHELIUM; FEMALE; FIBROBLASTS; HUMANS; MICROVESSELS; MIDDLE AGED; SCLERODERMA, SYSTEMIC; SKIN; TRANSFORMING GROWTH FACTOR BETA;

EID: 84947984934     PISSN: 03946320     EISSN: None     Source Type: Journal    
DOI: 10.1177/0394632015572750     Document Type: Article

References (35)

1. Korn JH (2001) Pathogenesis of systemic sclerosis. In: Koopman WJ (Ed.) Arthritis and Allied Conditions. Baltimore, MD: Wiliams & Wilkins, pp. 1643-1654.
2. Wigley FM (1996) Raynaud's phenomenon. Rheumatic Disease Clinics of North America 22: 765-781.
3. Belch JJP (1991) Raynaud's phenomenon: its relevance to scleroderma. Annals of the Rheumatic Disease 50: 839-845.
4. Le Roy EC (1975) Pathogenesis of systemic sclerosis: a vascular hypothesis. Seminars in Arthritis and Rheumatism 4: 351-368.
5. Herrick AL, Illingworth K and Blann A (1996) von Willebrand factor, thrombomodulin, thromboxane, thromboglobulin and markers of fibrinolysis in primary Raynaud's phenomenon and systemic sclerosis. Annals of the Rheumatic Diseases 55: 122-127.
6. Salojin KV, Le Tonquze M and Saraux A (1997) Antiendothelial cell antibodies: Useful markers of systemic sclerosis. American Journal of Medicine 102: 178-185.
7. Negi S (1998) Antiendothelial cell antibodies in scleroderma correlate with severe digital ischemia and pulmonary arterial hypertension. Journal of Rheumatology 3: 462-466.
8. Arends SJ, Damoiseaux JG, Duijvestijn AM, et al. (2013) Functional implications of IgG anti-endothelial cell antibodies in pulmonary arterial hypertension. Autoimmunity 46: 463-470.
9. Belizna C and Cohen Tervaert JW (1997) Specificity, pathogenicity, and clinical value of endothelial cell antibodies. Seminars in Arthritis and Rheumatism 27: 98-109.
10. Sasamori Y and Mori H (1997) Effects of anti-endothelial cell antibody in pre-eclampsia on endothelin-1 release from cultured endothelial cells. Immunology & Cell Biology 75: 340-344.
11. Yoshio T, Masuyama J, Mimori A, et al. (1995) Endothelin-1 release from cultured endothelial cells induced by sera from patients with systemic lupus erythematosus. Annals of the Rheumatic Diseases 54: 361-365.
12. Endemann DH (2004) Endothelial dysfunction. Journal of the American Society of Nephrology 15: 1983-1992.
13. Meroni PL, Khamashta MA, Youinou P et al. (1995) Mosaic of anti-endothelial antibodies. Review of the first international workshop on anti-endothelial antibodies: Clinical and pathological significance. Lupus 4: 95-99.
14. Youinou P, Meroni PL, Khamashta MA et al. (1995) A need for standardization of the anti-endothelial cell antibody test. Immunology Today 16: 363-364.
15. Chan TM and Chen KP (1997) Identification of endothelial cell membrane proteins that bind anti-DNA antibodies from patients with systemic lupus erythematosus by direct or indirect mechanisms. Journal of Autoimmunity 10: 433-439.
16. Drouet C, Nissou MF, Ponard D, et al. (2003) Detection of antiendothelial cell antibodies by an enzyme-linked immunosorbent assay using antigens from cell lysate: Minimal interference with antinu-clear antibodies and rheumatoid factors. Clinical and Diagnostic Laboratory Immunology 10: 934-939.
17. van den Hoogen, Khanna D, Fransen J et al. (2013) 2013 classification criteria for systemic sclerosis: An American College of Rheumatology/European League against Rheumatism collaborative initiative. Arthritis and Rheumatology 65: 2737-2747.
18. Leroy EC, Black C, Fleischmajer R et al. (1988) Scleroderma (systemic sclerosis): Classification, subsets and pathogenesis. Journal of Rheumatology 15: 202-205.
19. Clements PJ, Lachenruch PA, Nq SC et al. (1990) Skin score. A semiquantitative measure of cutaneous involvement that improves prediction of prognosis in systemic sclerosis. Arthritis and Rheumatology 33: 1256-1263.
20. Bradford MM (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Analytical Biochemistry 72: 48-254.
21. Laemmli UK (1970) Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227: 680-685.
22. Navarro M, Cervera R, Font J, et al. (1997) Anti-endothelial cell antibodies in systemic autoimmune diseases: Prevalence and clinical significance. Lupus 6: 521-526.
23. Miura K, Aoun K, Yoshida S et al. (2012) Autoantibodies directed against labile epitopes on cell surface proteins in autoimmune disease patients: Proposal of a novel ELISA for the detection of anti-endothelial cell antibodies. Journal of Immunological Methods 382: 32-39.
24. Kahaleh MB (1992) The role of vascular endothelium in fibroblast activation and tissue fibrosis, particularly in scleroderma (systemic sclerosis) and pachydermo-periostosis (primary hypertrophic osteoarthropathy). Clinical and Experimental Rheumatology 10: 5-6.
25. Etoh T, Igarashi A, Iozumi K et al. (1990) The effects of scleroderma sera on endothelial cell survival in vitro. Archives of Dermatological Research 282: 516-519.
26. Abraham D and Distler O (2007) How does endothelial cell injury start? The role of endothelin in systemic sclerosis. Arthritis Research & Therapy 9(S): S2.
27. Shi-Wen X, Denton CP, Dashwood MR et al. (2001) Fibroblast matrix gene expression and connective tissue remodeling: Role of endothelin-1. Journal of Investigative Dermatology 116: 417-425.
28. Shi-Wen X, Chen Y, Denton CP, et al. (2004) Endothelin-1 promotes myofibroblast induction through the ETA receptor via a rac/phosphoinositide 3-kinase/Akt-dependent pathway and is essential for the enhanced contractile phenotype of fibrotic fibroblasts. Molecular and Cellular Biology 15: 2707-2719.
29. Yamamoto T, Takahashi Y, Kuno S et al. (1997) Effects of anti-endothelial cell antibody in pre-eclampsia on endothelin-1 release from cultured endothelial cells. Immunology & Cell Biology 75: 340-344.
30. Drenk F and Deiker HRG (1988) Pathophysiological effects of endothelial cytotoxic activity derived from sera of patients with progressive systemic sclerosis. Journal of Rheumatology 15: 468-474.
31. Holt CM, Lindsey N, Moult J et al. (1989) Antibody-dependent cellular cytotoxicity of vascular endothelium: Characterization and pathogenic associations in systemic sclerosis. Clinical and Experimental Immunology 78: 359-365.
32. Del Papa N, Meroni PL, Barcellini W, et al. (1992) Antibodies to endothelial cells in primary vasculitis mediate in vitro endothelial cytotoxicity in the presence of normal peripheral blood mononuclear cells. Clinical Immunology and Immunopathology 63: 267-274.
33. Sgonc R, Gruschwitz MS, Boeck G et al. (2000) Endothelial cell apoptosis in systemic sclerosis is induced by antibody-dependent cell-mediated cytotocicity via CD95. Arthritis & Rheumatology 43: 2550-2562.
34. Denton CP, Xu S, Welsh KI et al. (1996) Scleroderma fibroblast phenotype is modulated by endothelial cell coculture. Journal of Rheumatology 23: 633-638.
35. Denton CP, Xu S, Black CM et al. (1997) Scleroderma fibroblasts show increased responsiveness to endothelial cell-derived IL-1 and bFGF. Journal of Investigative Dermatology 108: 269-274.